Franklin Resources
XENE icon

Franklin Resources’s Xenon Pharmaceuticals XENE Stock Holding History

Franklin Resources’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.8M Buy
1,437,712
+157,135
+12% +$8.72M 0.02% 508
2026
Q1 		$74.5M Buy
1,280,577
+522,518
+69% +$24.1M 0.02% 516
2025
Q4 		$34M Buy
758,059
+62,159
+9% +$2.61M 0.01% 770
2025
Q3 		$27.9M Buy
695,900
+29,434
+4% +$1.04M 0.01% 844
2025
Q2 		$20.9M Buy
666,466
+175,346
+36% +$5.72M 0.01% 916
2025
Q1 		$16.5M Sell
491,120
-84,470
-15% -$3.21M ﹤0.01% 956
2024
Q4 		$22.6M Buy
575,590
+9,675
+2% +$400K 0.01% 866
2024
Q3 		$23.6M Sell
565,915
-12,950
-2% -$522K 0.01% 843
2024
Q2 		$22.6M Buy
578,865
+36,576
+7% +$1.46M 0.01% 817
2024
Q1 		$23.3M Buy
542,289
+248,464
+85% +$11.4M 0.01% 817
2023
Q4 		$13.5M Buy
293,825
+121,213
+70% +$4.28M 0.01% 860
2023
Q3 		$5.9M Hold
172,612
– – ﹤0.01% 1043
2023
Q2 		$6.65M Buy
172,612
+3
+0% +$119 ﹤0.01% 1033
2023
Q1 		$6.18M Buy
+172,609
New +$6.38M ﹤0.01% 1047

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Franklin Resources's XENE Position: Q2 2026 in Review

Franklin Resources increased its Xenon Pharmaceuticals (XENE) stake by 12% in Q2 2026, buying an estimated $8.72M and bringing the position to 1,437,712 shares worth $86.8M. The position accounts for 0.02% of the portfolio, ranked #508.

Franklin Resources first reported a position in XENE in Q1 2023 and has held it in 14 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Franklin Resources held 1,437,712 shares of Xenon Pharmaceuticals worth $86.8M as of Q2 2026.
  • Franklin Resources bought 157,135 Xenon Pharmaceuticals shares in Q2 2026, an estimated $8.72M.
  • Xenon Pharmaceuticals made up 0.02% of Franklin Resources's portfolio in Q2 2026, its #508 holding.
  • Franklin Resources first reported a position in Xenon Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.